b r i e f c o m m u n i c a t i o n s High-percent mammographic density adjusted for age and body mass index is one of the strongest risk factors for breast cancer. We conducted a meta analysis of five genome-wide association studies of percent mammographic density and report an association with rs10995190 in ZNF365 (combined P = 9.6 × 10 −10 ). Common variants in ZNF365 have also recently been associated with susceptibility to breast cancer.
Percent mammographic density reflects the proportion of stromal and epithelial tissues in relation to fat tissue in the breast. Women with more than 75% dense tissue in the breast are at a fourfold to fivefold greater risk of breast cancer than women of the same age and body mass index (BMI) with little or no dense tissue [1] [2] [3] . Percent mammographic density has thus been considered an intermediate phenotype of breast cancer [4] [5] [6] [7] , and identifying its determinants may provide new insights into the etiology of breast cancer.
Lifestyle factors including age, parity, BMI and exogenous hormone levels explain only 20-30% of the between-women variation in percent mammographic density 8 . It has been estimated that 61-67% of the residual variation can be attributable to genetic factors 9 , but linkage and candidate gene-association studies have been largely unsuccessful in reproducibly identifying loci related to mammographic density.
To this end, we conducted a meta analysis of five genome-wide association studies (GWAS) of percent mammographic density adjusted for age and BMI within the Marker Of DEnsity (MODE) consortium, which includes the Nurses' Health Study (NHS) (n = 1,590), the Singapore and Swedish Breast Cancer Study (SASBAC) (n = 1,258), the European Prospective Investigation Into Cancer and Nutrition (EPIC Norfolk) (n = 1,142), the Minnesota Breast Cancer Family study (MBCFS) (n = 571) and the TORONTO/MELBOURNE study (n = 316). The total sample size was 4,877 women. All women were of self-described European descent and the majority (89%) were postmenopausal at the time of mammogram.
The study design, population characteristics and genotyping platforms varied across the studies (Supplementary Tables 1-3 ). For all studies, the percent mammographic density was measured using the Cumulus software 10 . Genotypes for more than 2 million SNPs were imputed within each study using Phase II data from individuals in the HapMap European CEU dataset. All studies except the TORONTO/MELBOURNE study used linear regression analyses, treating percent mammographic density as a quantitative trait. The TORONTO/MELBOURNE study selected women in the top and bottom 10% of percent mammographic density and treated women with high density as cases and women with low density as controls in a logistic regression model. The differences in study design (extreme sampling versus continuous trait) did not allow us to perform a meta analysis based on the estimated effect size in each study, as units of density measurement were not comparable across studies 11 . Instead, we derived a combined test for each SNP by combining P values and the direction of association for each study weighted by the square root of the sample size and the study-specific inflation factor. We calculated an effective sample size for the TORONTO/MELBOURNE study (n = 1,109) to account for that study's sampling of women in the tails of the distribution (Supplementary Methods) .
The quantile-quantile plot and Manhattan plots are shown in Supplementary Figures 1 and 2 . The overall genetic inflation factor (λ) was 1.033. Although no SNP met the commonly used genomewide significance criterion of P < 5 × 10 −8 , six SNPs within the same Common variants in ZNF365 are associated with both mammographic density and breast cancer risk Supplementary Table 4 ).
Researchers from a recent GWAS 12 including 3,659 cases with breast cancer and 4,897 controls from the UK in the first stage and 12,576 cases with breast cancer and 12,223 controls in the second stage found that the rs10995190 A allele in ZNF365 was associated with decreased breast cancer risk (odds ratio (OR) = 0.86, 95% CI 0.82-0.91, P = 5.1 × 10 −15 ) 12 . The rs10995190 A allele is in high LD with the rs10995195 C allele (pairwise r 2 = 0.94 in the HapMap CEU population) and was ranked third in our meta analysis of percent mammographic density (P = 5.7 × 10 −7 ; Fig. 1) .
We attempted to replicate the association between rs10995190 and percent mammographic density in 1,690 women from the Mayo Clinic Breast Cancer Study (MCBCS) genotyped as a part of the replication in a previous breast cancer case-control GWAS 12 and in an additional 1,145 women without breast cancer from the Sisters in Breast Screening Study (SIBS) through in silico replication (Supplementary Methods). We found that the A allele of rs10995190 was associated with lower percent mammographic density in our replication studies (P = 0.0004), resulting in a combined P = 9.6 × 10 −10 ( Table 1) . Adjusting for breast cancer case-control status in NHS and MCBCS (P = 6.4 × 10 −9 ) or excluding breast cancer cases (P = 1.1 × 10 −7 ) did not change the statistical significance of this association. For two of the three case-control studies (NHS and MCBCS), there was a significant association between rs10995190 and mammographic density among the controls ( Table 1) . Therefore, we find it unlikely that the association between rs10995190 and mammographic density is driven by confounding caused by the inclusion of breast cancer cases. Across studies with genotype data for rs10995190 (not considering studies with imputed data), the mean change in percent mammographic density per minor allele was −2.01. Based on this estimate, rs10995190 would explain ~0.5% of the variance in percent mammographic density.
To assess the extent to which the observed association between rs10995190 and breast cancer risk might be mediated through mammographic density, we estimated the association between rs10995190 and breast cancer risk before and after adjustment for mammographic density using case-control data from NHS, SASBAC and MCBCS (Supplementary Table 5 ). From the pooled analysis, including 2,107 breast cancer cases and 2,433 controls, we observed a significant association between rs10995190 and breast cancer risk, with an effect size similar to that previously reported (OR = 0.85, 95% CI 0.76-0.96, P = 0.008) 12 . Adjusting for mammographic density slightly attenuated the association (OR = 0.90, 95% CI 0.80-1.01, P = 0.09). These results suggest that genetic variation in ZNF365 could influence breast cancer risk through an influence on the proportion of dense tissue in the breast, although it remains possible that the same locus influences both phenotypes independently.
In addition, we examined if any other known breast cancer SNPs were associated with mammographic density in our study Table 6 ). Out of 22 SNPs tested (excluding rs10995190), two showed an association with mammographic density: rs2046210 (ESRI, P = 0.005) and rs3817198 (LSP1, P = 0.04). Both associations were in the expected direction as determined by corresponding breast cancer associations. We also examined these associations stratified by case-control status, recognizing the lower statistical power due to the smaller sample size ( Supplementary Table 6 ).
A potential limitation in this study is the inherent measurement error in mammographic density. In all seven studies, mammographic density was read using the same computer-assisted thresholding method, which has been shown to be highly reproducible, with intraand inter-reader reproducibility within sites generally greater than 0.9 (ref. 10 ). In addition, the European studies used the medio-lateral oblique view, whereas other studies used the cranio-caudal view. Although the percent density measurements from the medio-lateral oblique view have been shown to be lower than those from the craniocaudal view 13, 14 , both measures are strong predictors of breast cancer risk. By conducting study-specific GWAS before pooling summary statistics in a meta-analysis, we minimized the impact of differences in density measurements across studies.
Mammographic density attenuated the association with breast cancer risk, suggesting that the influence of ZNF365 on breast cancer risk may be mediated in part by mammographic density. Given that there is measurement error in our phenotype, our ability to show mediation through mammographic density was reduced. Nonetheless, these results show how an intermediate phenotype can help shed light on the mechanisms underlying observed SNP-disease associations. The association with rs10995190, although highly statistically significant, explains only 0.5% of the variance in percent mammographic density. Further GWAS analyses with larger sample sizes will most likely result in identification of additional variants.
In summary, we report a new association between common genetic variants in ZNF365 and percent mammographic density adjusted for age and BMI. This locus was also recently identified as being associated with breast cancer susceptibility, suggesting that genetic variation in the ZNF365 locus may influence breast cancer risk through an influence on the proportion of dense tissue in the breast.
Note: Supplementary information is available on the Nature Genetics website.
